OBINUTUZUMAB

obinutuzumab 1 g/40 mL injection, 40 mL vial

OBINUTUZUMAB (13787P)

obinutuzumab 1 g/40 mL injection, 40 mL vial
13787P
Body System:
Manner of administration:Injection
Public
Chemotherapy Items for Public Hospital use
Authority Required (STREAMLINED)

Restriction  18618

Indication: Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
Treatment phase: For combination use with acalabrutinib from treatment cycles 2 to 7 inclusive in first-line therapy
Quantities & Cost
Max amount # of repeats DPMA Max safety net General Patient Charge
Max amount: 1000 mg # of repeats: 7 DPMA: $4,390.47 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Gazyva
(obinutuzumab 1 g/40 mL injection, 40 mL vial)